Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Catalent Inc (NY: CTLT ) 55.48 -0.32 (-0.57%) Official Closing Price Updated: 7:00 PM EDT, Apr 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Catalent Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating April 12, 2024 BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled... Via Benzinga Beyond The Numbers: 6 Analysts Discuss Catalent Stock April 04, 2024 Via Benzinga Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics? March 26, 2024 All three of these high-flying stocks could have more room to run. Via The Motley Fool Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities March 23, 2024 Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. Via Talk Markets Did Novo Nordisk Just Get a Jump on Eli Lilly? March 19, 2024 A recent FDA announcement may have just put one company in the lead. Via The Motley Fool Exposures Product Safety (CTLT) - Analyzing Catalent's Short Interest February 28, 2024 Via Benzinga In-Depth Examination Of 5 Analyst Recommendations For Catalent February 20, 2024 Via Benzinga Earnings Outlook For Catalent February 08, 2024 Via Benzinga Why Catalent Stock Soared Today February 05, 2024 Catalent has agreed to be acquired by Novo Nordisk's parent company. Via The Motley Fool The Top 3 Pharma Stocks to Buy in March2024 March 09, 2024 Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge. Via InvestorPlace Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug March 08, 2024 "Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect significant weight loss and cardiovascular benefits. Phase 2 trial begins in late... Via Benzinga Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk March 06, 2024 Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising... Via Benzinga Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why March 05, 2024 Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus. Via The Motley Fool Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla March 01, 2024 U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, with other companies also reaching milestones. Via Benzinga Topics ETFs Stocks Exposures US Equities Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit) February 29, 2024 Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed. Via Benzinga Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors February 26, 2024 Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. Via Benzinga Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest? February 14, 2024 Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielded from bearish pressures. Via Benzinga Topics Stocks Exposures US Equities Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs February 12, 2024 Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market... Via Benzinga Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now? February 11, 2024 Even more revenue is on the way from additional sales of Wegovy. Via The Motley Fool Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited February 10, 2024 Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic. Via The Motley Fool US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March February 09, 2024 The upward momentum that has been in play in recent sessions could cushion the market, especially as most major indices are in uncharted territory. Via Benzinga Earnings Scheduled For February 9, 2024 February 09, 2024 Companies Reporting Before The Bell • TELUS (NYSE:TU) is expected to report quarterly earnings at $0.23 per share on revenue of $5.24 billion. Via Benzinga The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry February 08, 2024 Novo Nordisk's groundbreaking weight-loss treatments are causing concern in the food industry. CEOs are seeking advice from the company. Via Benzinga Catalent's Bloomington Plant Making Novo Nordisk's Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns February 07, 2024 Novo Nordisk faces manufacturing challenges and drug shortages for diabetes and weight loss drugs, impacting Wegovy and Ozempic. Via Benzinga Exposures Product Safety Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks February 06, 2024 Thanks to weight loss and obesity drugs, Eli Lilly and Novo Nordisk could become the first trillion-dollar stocks in the pharma industry. Via InvestorPlace Catalent Analysts Raise Their Forecasts Following Acquisition News February 06, 2024 On Monday, Catalent, Inc. (NYSE: CTLT) announced it will be acquired by Novo Holdings. Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash. Via Benzinga Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday February 06, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Why Novo Nordisk Stock Crushed the Market on Monday February 05, 2024 The pharmaceutical giant will receive three manufacturing facilities from its parent company's latest acquisition. Via The Motley Fool Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday? February 05, 2024 Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for... Via Benzinga Topics Economy Exposures Interest Rates Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record February 05, 2024 Amgen is looking to rival Eli Lilly and Novo Nordisk in weight-loss drugs. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.